Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 10/20 | 0.62 |
| ▸ | AURKA | O14965 | 6/20 | 0.62 |
| ▸ | CDK8 | P49336 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 5/20 | 0.55 |
| ▸ | FLT3 | P36888 | 4/20 | 0.55 |
| ▸ | FLT4 | P35916 | 3/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.55 |
| ▸ | CSF1R | P07333 | 2/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | FLT1 | P17948 | 2/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 3/20 | 0.53 |
| ▸ | PLK4 | O00444 | 3/20 | 0.52 |
| ▸ | CDK1 | P06493 | 3/20 | 0.52 |
| ▸ | MARK3 | P27448 | 3/20 | 0.52 |
| ▸ | JAK3 | P52333 | 3/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546547 | 0.89 | AURKB (0.77) | AURKBAURKACDK8KDRFLT3 | |
| SCHEMBL545731 | 0.86 | AURKB (0.68) | AURKBAURKACDK8KDRFLT3 | |
| SCHEMBL546160 | 0.85 | AURKB (0.84) | AURKBAURKACDK8KDRKIT | |
| SCHEMBL546617 | 0.78 | AURKB (1.00) | AURKBAURKACDK8KDRFLT3 | |
| SCHEMBL545824 | 0.76 | AURKB (1.00) | AURKBAURKACDK8 | |
| SCHEMBL545527 | 0.75 | AURKB (1.00) | AURKBAURKAKDRFLT3KIT | |
| SCHEMBL545988 | 0.75 | KDR (0.70) | AURKBAURKAKDRFLT3FLT4 | |
| SCHEMBL422939 | 0.73 | KDR (0.74) | AURKBAURKAKDRFLT3FLT4 | |
| SCHEMBL421486 | 0.72 | KDR (0.86) | AURKBAURKAKDRFLT3FLT4 | |
| SCHEMBL16456826 | 0.71 | KDR (0.66) | AURKBAURKAKDRFLT3FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170834-B1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBVIE INC (US) | 2014-01-08 | — | — | EP | claimed |
| US-8110572-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-07 | — | — | US | claimed |
| EP-2170834-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | claimed |
| US-20090054430-A1 | Inhibitors of Protein Kinases | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | claimed |
| WO-2009012312-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | claimed |
| EP-2170834-B1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBVIE INC (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8110572-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-07 | — | — | US | disclosed |
| EP-2170834-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090054430-A1 | Inhibitors of Protein Kinases | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009012312-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054430-A1 | Inhibitors of Protein Kinases | AURKC, AURKB, PLK1 | AURKB 2/4885AURKA 4/4885CDK8 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.